SGEN Share Price

Open 66.41 Change Price %
High 67.87 1 Day -0.01 -0.01
Low 66.27 1 Week -5.15 -7.17
Close 66.70 1 Month 9.70 17.02
Volume 714038 1 Year 27.59 70.54
52 Week High 75.36
52 Week Low 26.02
SGEN Important Levels
Resistance 2 68.18
Resistance 1 67.57
Pivot 66.95
Support 1 65.83
Support 2 65.22
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Seattle Genetics, Inc. (NASDAQ: SGEN)

SGEN Technical Analysis 4
As on 2nd Dec 2016 SGEN Share Price closed @ 66.70 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 43.54 & Buy for SHORT-TERM with Stoploss of 58.70 we also expect STOCK to react on Following IMPORTANT LEVELS.
SGEN Target for December
1st Target up-side 77.79
2nd Target up-side 86.88
3rd Target up-side 95.98
1st Target down-side 51.83
2nd Target down-side 42.74
3rd Target down-side 33.64
SGEN Other Details
Segment EQ
Market Capital 2955180288.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.seattlegenetics.com
SGEN Address
SGEN
21823 30th Drive SE
Bothell, WA 98021
United States
Phone: 425-527-4000
Fax: 425-527-4001
Interactive Technical Analysis Chart Seattle Genetics, Inc. ( SGEN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Seattle Genetics, Inc.
SGEN Business Profile
Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.